Results of the ADAURA trial led to recommendation of adjuvant osimertinib in patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC who received previous adjuvant platinum-based chemotherapy (7). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.